Biogen’s MS Pill Delayed in Europe as Patent Extended
This article is for subscribers only.
Biogen Idec Inc., the world’s biggest maker of multiple sclerosis drugs, said a European regulatory decision on its new pill will be delayed until the second half of the year after a patent on the medicine was extended.
Biogen said it’s seeking to clarify Tecfidera’s regulatory exclusivity status in Europe. A European patent on the pill was extended yesterday until 2028 and covers the expected 480-milligram dose planned for sale, the Weston, Massachusetts-based company said today in a regulatory filing.